Collectively, our data demonstrate a role for MERTK as a mediator of oncogenic signaling and driver of residual tumor growth in EGFRMT NSCLCs treated with OSI and provide strong rationale for treatment of EGFRMT NSCLC patients with OSI and MRX-2843 combined. Here, MERTK is linked to neoplasm.